Methycobal®

Methycobal® is a mecobalamin preparation for treatment of peripheral neuropathies. Methycobal® contains mecobalamin, a vitamin B12 coenzyme that occurs in the blood and the cerebrospinal fluid. It is taken up by nerve tissues more actively and extensively than other homologue of vitamin B12. Biochemically, Methycobal®accelerates the metabolic pathways of nucleic acids, proteins and lipids through its involvement in the transmethylation reaction. Thus, it exerts a repairing effect on injured nerve tissues. Clinically, Methycobal® is the first pharmaceutical product that has been shown, by double-blind clinical studies, to be effective and useful for the treatment of numbness, pain, and paralysis due to peripheral neuropathies such as Diabetic Neuropathy and Carpal Tunnel Syndrome.

Methycobal® Tablets

Indication

Peripheral neuropathies

Dosage and Administration

Oral dosage: 1500µg daily in 3 divided doses, dosage may be adjusted depending on patient’s age and symptoms.

Adverse Reactions and Precautions

Adverse reactions were reported in 146 out of 15,180 patients (0.96%).The most common adverse reactions include gastrointestinal symptoms such as anorexia in 52 patients (0.34%), gastrointestinal disorders in 38 patients (0.25%), nausea/vomiting in 18 patients (0.18%), diarrhea in 17 patients (0.11%), and skin rash in 14 patients (0.09%). General Precautions: Methycobal® should not be administered for extensive periods (months) to patients who show no clinical response. Other Precautions: Prolonged use of larger doses of Methycobal® is not recommended for patients whose occupation requires handling mercury or its compounds.

Methycobal® Injection

Indication

Peripheral neuropathies

Megaloblastic anemia caused by vitamin B12 deficiency

Dosage and Administration

Injection: 500µg (1 ampule) three times a week, dosage may be adjusted depending on patient’s age and symptoms.

Adverse Reactions and Precautions

Adverse reactions were reported in 13 of 2,872 patients (0.45%)

1)   Clinically significant adverse reactions (incidence unknown)

Anaphylactoid reactions

Anaphylactoid reaction such as decrease in blood pressure or dyspnea may occur. Patients should be carefully observed. In the event of such symptoms, treatment should be discontinued immediately and appropriate measures taken.

2)   Other adverse reactions

Note: In the event of such symptoms, treatment should be discontinued. For further product information kindly refer to the prescribing information.

 

Reference Methycobal® product insert.

This is the website of Eisai (Hong Kong) Co. Ltd. This site is intended for Hong Kong residents only. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

Copyright © Eisai (Hong Kong) Co., Ltd. All Rights Reserved.